Salute e Benessere

Global Electric Actuator Market Growth Accelerates Amid Rising Adoption in Water…

The global Electric Actuator Market revenue was USD 2549 Million in 2022 and is forecast to a readjusted size of USD 3297.1 Million by 2029 with a CAGR of 3.7% during the forecast period (2023-2029). The global Electric Actuator Market revenue wasUSD 2549 Millionin 2022 and is forecast to a readjusted size ofUSD 3297.1 Millionby 2029 with a CAGR of 3.7% during the forecast period (2023-2029). Get Free Sample Report on Electric Actuator Market What are the key factors...
PR Newswire
13/10/2025

Waters Launches Charge Detection Mass Spectrometry Technology to Accelerate the…

"Waters continues to make strategic investments in large molecules, recognizing that advanced tools for bioanalytical characterization play a critical role in driving therapeutic breakthroughs. Today, we are proud to introduce the first-of-its-kind Xevo Charge Detection Mass Spectrometer, enabling the precise analysis of previously unmeasurable molecules," said Udit Batra, Ph.D., President and Chief Executive Officer, Waters Corporation. "We believe the Xevo CDMS will accelerate…
PR Newswire
13/10/2025

Evaxion to present a breadth of data from phase 2 trial with AI-designed…

Presentation will cover two-year clinical efficacy, immunogenicity and safety dataData will be presented at an oral session on October 17, 2025, followed by a webinar on October 22, 2025, providing further insights into the clinical findings COPENHAGEN, Denmark, October 13, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will present a wide range of data from its phase 2 trial with lead...
Nasdaq GlobeNewswire
13/10/2025

Thousand Oaks Biologics Shanghai ADC Site receives EU QP Declaration

Throughout the audit, the inspection team recognized Thousand Oaks Biologics Shanghai's state-of-the-art facilities, stringent quality management systems, and highly skilled technical team, concluding that the site meets EU GMP requirements. Throughout the audit, the inspection team recognized Thousand Oaks Biologics Shanghai's state-of-the-art facilities, stringent quality management systems, and highly skilled technical team, concluding that the site meets EU GMP requirements. Since its...
PR Newswire
13/10/2025

Theriva™ Biologics Announces Upcoming Presentations at Medical Meetings

- VCN-01 expanded mPDAC data from VIRAGE Phase 2b trial to be presented at ESMO 2025 -- SYN-004 Interim blinded safety and pharmacokinetic data to be presented at IDWeek 2025 - Rockville, Md., Oct.13, 2025(GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced upcoming presentations at the European...
Nasdaq GlobeNewswire
13/10/2025

Fundus Camera Market Insights: Segmentation by Type and Technology

Transparency Market Research
13/10/2025

Scintillator Market to Reach $643 million by 2024 in short term and $1,062.5…

Download Sample Pages of Research Overview:https://www.alliedmarketresearch.com/request-sample/A08822 Download Sample Pages of Research Overview:https://www.alliedmarketresearch.com/request-sample/A08822 Prime determinants of growth The scintillator market is primarily driven by rising applications in medical imaging, homeland security, and nuclear safety, as scintillators enable accurate radiation detection and high-quality imaging. However, high production costs and limited...
PR Newswire
13/10/2025

LTS expands its CDMO capabilities with the acquisition of Renaissance Lakewood

The acquisition of Renaissance marks a significant milestone in LTS's strategy to expand its capabilities in the CDMO space. Renaissance brings deep expertise, state-of-the-art manufacturing infrastructure, and a talented workforce of approximately 500 employees. This move enables LTS to offer a broader range of drug delivery solutions and strengthens its position within the CDMO community. The acquisition of Renaissance marks a significant milestone in LTS's strategy to expand its…
PR Newswire
13/10/2025

CHAPPER healthcare, AscellaHealth’s Global Pharmaceutical Distributor…

This milestone marks half a century of innovation, reliability and access to life-saving medicines worldwide CHAPPER healthcare,AscellaHealth’sglobal pharmaceutical wholesaler, distributor, and service provider, proudly celebrates its 50th anniversary—marking five decades of delivering critical access to licensed and unlicensed medicines to patients in more than 80 countries across six continents. With subsidiaries in Ireland and the United Arab Emirates, and a strategic warehousing hub...
Nasdaq GlobeNewswire
13/10/2025

Zinzino AB (publ.): Pioneering Gut Health Testing With a Simple Finger Prick

Research indicates that a balanced gut supports the whole body. More than 70% of the body's immune system is in the gut, and every gut microbiome is different.¹ Traditional microbiome (stool) tests only look at the diversity of microbes present in the gut. Zinzino's Gut Health Test is the first of a new generation of gut health tests that measure gut function and whether these processes strengthen or strain the immune system.² Individuals can then use the test results to take proactive steps to…
PR Newswire
13/10/2025

Lupin Announces Presentation of Phase 1 Data on LNP3693 (STING agonist) at the…

"This marks another important milestone for us. Following our successful presentation of LNP7457, a PRMT5 inhibitor, at ASCO in June 2025, it is a privilege to present the findings of another Phase 1 clinical trial for LNP3693, a STING agonist, at ESMO. ESMO's acknowledgment of the clinical research conducted in India underscores the proficiency of our team in oncology drug discovery, research, and clinical development," said Vinita Gupta, CEO, Lupin. "This marks another important…
PR Newswire
13/10/2025

Implantica completes FDA 100-Day Meeting for RefluxStop® PMA application

Dr. Peter Forsell, CEO and founder of Implantica, says, "We are very encouraged by the constructive outcome of the FDA 100-Day meeting. The dialogue provided valuable clarity on what FDA requires in the remaining steps in the PMA review process. With this feedback, Implantica now has the necessary insight to finalize the remaining pieces of information that FDA would like to see." Dr.Peter Forsell, CEO and founder of Implantica, says, "We are very encouraged by the constructive…
PR Newswire
13/10/2025

AnnJi Showcases Clinical Breakthrough of AJ201 at WMS 2025

Dr. Andrew Pai presented the latest preclinical research of Rosolutamide (JM17), the active ingredient of AJ201. JM17 demonstrated multi-pathway benefits in SBMA mouse model, including enhanced mitochondrial function, reduced inflammation and fibrosis, as well as improved structural organization of muscle fibers. Upstream regulator analysis further confirmed the inhibition of pro-inflammatory mediators (TNF-α, IL-6, TGF-β) alongside activation of protective signaling pathways. These findings…
PR Newswire
13/10/2025

Cumulus Neuroscience Presents Data at the International Society for CNS Clinical…

The first poster, presented at ECNP, titled, "Deploying User-Friendly Portable EEG to Measure Response to a Novel Antidepressant with Resting and Task-Driven Neurophysiological Endpoints," reported interim data from a Phase1bstudy conducted in partnership with Delix Therapeutics. The poster featured data evaluating the pharmacodynamics, safety, and tolerability of a novel neuroplastogen, DLX-001, in people with MDD. The Phase1bstudy was designed to show early evidence of...
PR Newswire
13/10/2025

POLYTECH Raises Visibility in The Guardian via Awareness Feature on Breast…

In the article, François Franca Franco Junior (POLYTECH's UK & Ireland General Manager) shares insights on how cutting-edge implant technology can improve patient outcomes. The Guardian piece notes that breast reconstruction is not merely cosmetic but "about comfort, confidence and long-term results," emphasizing the importance of informed choice for women after mastectomy. It introduces B-Lite®, the world's first and only lightweight breast implant, which is up to 30% lighter than…
PR Newswire
13/10/2025

Bavarian Nordic shareholders are reminded of expiry of the offer period…

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTIONCOPENHAGEN, Denmark, 13 October 2025– Reference is made to the company announcement dated 26 August 2025 (no. 24/2025) and the company announcement dated 29 September 2025 (no. 27/2025) regarding the all-cash voluntary board-recommended public takeover offer to acquire all of the issued and...
Nasdaq GlobeNewswire
13/10/2025

Lundbeck's bexicaserin receives Breakthrough Therapy Designation in China for…

"We are honored that bexicaserin has been granted Breakthrough Therapy Designation, recognizing the potential of our innovative approach to advancing treatment in one of the most challenging areas of epilepsy," said Johan Luthman, EVP and Head of Research & Development at Lundbeck. "Drawing on our expertise in neuroscience, and past experiences with epilepsy therapies, we are deeply committed driving the global Phase 3 clinical program forward. Obtaining BTD for the program in…
PR Newswire
13/10/2025

ISTH marks World Thrombosis Day with urgent global call to action

Observed annually on October 13, World Thrombosis Day underscores the urgent need for early detection and prevention of thrombosis, commonly known as blood clots. Thrombosis contributes to the world's three leading cardiovascular killers: heart attack, stroke and venous thromboembolism (VTE). Yet awareness remains critically low. Each year, an estimated 10 million cases of hospital-associated blood clots occur globally, resulting in up to 100,000 deaths in the United States alone. Many of these…
PR Newswire
13/10/2025

ONWARD Medical Provides Preliminary Q3 2025 Update Highlighting Accelerating…

Commercial traction : 40 ARC-EX ®Systems were sold in Q3, demonstrating continued strong commercial traction for the Company’s groundbreaking external spinal cord stimulation technology. More than 50 clinics across the US are now equipped with the ARC-EX System.Regulatory milestones : The Company received CE Mark certification for the ARC-EX System, indicated to improve hand strength and sensation after SCI, both in the clinic and at home. Additionally, the US Food and Drug...
Nasdaq GlobeNewswire
13/10/2025

Roche data at ESMO 2025 showcase advances in science and cancer care across…

Key presentations include: Giredestrant: Primary results from the phase III evERA Breast Cancer study, the first positive head-to-head phase III trial investigating a selective oestrogen receptor (ER) degrader-containing regimen versus a standard of care combination in the post-cyclin-dependent kinase inhibitor setting for people with ER-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer. 1,2The study met both co-primary...
Nasdaq GlobeNewswire
13/10/2025

Q3 2025 Qualitative Update: Tecan reports mid-single-digit local currency growth…

Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Q3 2025 Qualitative Update: Tecan reports mid-single-digit local currency growth in the third quarter and confirms full-year 2025 outlookMännedorf, Switzerland, October 13, 2025 –The Tecan Group (SIX Swiss Exchange: TECN) today provided a qualitative update on its performance for the third quarter of 2025. Sales for the third quarter increased by a mid-single-digit percentage in local...
Nasdaq GlobeNewswire
13/10/2025

EarlyHealth Group Acquires CYB3R, Gulf’s Fastest-Growing Cybersecurity Firm

CYB3R, owned by tech entrepreneurs Alex Halsall and Jack Tupper, has rapidly gained prominence by securing critical infrastructure and sensitive data in regulated industries across the Middle East and Europe. By embedding CYB3R’s capabilities into EarlyHealth’s global platform, the partnership will scale operations internationally and deliver turnkey solutions that safeguard clinical studies, institutional programs, and government initiatives.“With a growing portfolio of 1,200...
Nasdaq GlobeNewswire
12/10/2025

Sandstone Easydrip™ Plus Pen Needles Debut in Turkey -- Patent‑Protected…

Key advantages Key advantages Market relevance As the first pen needle with a patent‑protected hexagonal hub available inTurkey, Easydrip™ Plus is already attracting interest from neighbouring countries and sets a practical alternative between premium global brands and low‑end generics. Availability & next steps Certifications Easydrip™ Plus is manufactured under a strict ISO 13485 quality system and holds CE Declaration of Conformity, meeting international safety...
PR Newswire
11/10/2025

FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release…

FDA approves UZEDY ®(risperidone) extended-release injectable suspension for subcutaneous use as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder in adults. 1 UZEDY (risperidone) extended-release injectable suspension for subcutaneous use is indicated for use every one or two months for the treatment of schizophrenia in adults. 1 This approval marks a significant step towards addressing the unmet needs of...
Nasdaq GlobeNewswire
10/10/2025
Altri  Comunicati